BTW, Ranbaxy filed a paragraph IV against Lipitor, claiming invalidity and non-infringement of the five patents listed in the FDA's Orange Book. Teva filed based on the technical defect in the '995 patent, which had been corrected later but rejected on other grounds.
Market Data 
Markets 
AI
